Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions

Li, Xinguo; Sun, Xiaonan; Wang, Bingyuan; Li, Yiling; Tong, Jing

doi:10.1016/j.ajps.2022.100771

Cited by 12 publications

(9 citation statements)

References 156 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pexastimogene devacirepvec (JX-594), a genetically modified vaccinia virus (VV), was approved as an orphan drug for the treatment of HCC in 2013 [ 202 ]. The viral thymidine kinase (TK) gene was deleted in JX-594 for its selective replication within TK-expressing tumors and GM-CSF as well as β-galactosidase was expressed to activate the immune response.…”

Section: Emerging Immunotherapiesmentioning

confidence: 99%

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Shen,

Zhu,

Xie

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs have been the major trend in this area. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective treatment for advanced HCC. However, the majority of HCC patients obtain limited benefits. Understanding the immunological rationale and exploring novel ways to improve the efficacy of immunotherapy has drawn much attention. In this review, we summarize the latest progress in this area, the ongoing clinical trials of immune-based combination therapies, as well as novel immunotherapy strategies such as chimeric antigen receptor T cells, personalized neoantigen vaccines, oncolytic viruses, and bispecific antibodies.

show abstract

Section: Emerging Immunotherapiesmentioning

confidence: 99%

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Shen,

Zhu,

Xie

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…In other studies, rAd‐p53 was combined with other therapies comprising 5‐FU administration, transarterial chemoembolization, or N‐Myc proto‐oncogene. [ 153 ] Other studies have been conducted in f hypopharyngeal squamous cell carcinoma (HPSCC). Patients have been treated with the combination of rAd‐p53 with CRT (chemotherapy) and previous Surgery (complete tumor surgical resection) with improved therapeutic effects.…”

Section: Genome Engineering Technologies For Cancer Treatmentmentioning

confidence: 99%

Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review

Gemayel,

Chebly,

Kourie

et al. 2024

Advanced Genetics

View full text Add to dashboard Cite

Cancer is one of the foremost causes of mortality. The human genome remains stable over time. However, human activities and environmental factors have the power to influence the prevalence of certain types of mutations. This goes to the excessive progress of xenobiotics and industrial development that is expanding the territory for cancers to develop. The mechanisms involved in immune responses against cancer are widely studied. Genome editing has changed the genome‐based immunotherapy process in the human body and has opened a new era for cancer treatment. In this review, recent cancer immunotherapies and the use of genome engineering technology are largely focused on.

show abstract

“…Virotherapy presents a novel immunotherapy modality for HCC. Oncolytic virotherapy (OVT) effectively induces antitumor responses through selective replication of oncolytic virus in cancerous tissues and killing HCC cells ( Li et al, 2023b ).…”

Section: Time and Targeted Therapies In Hccmentioning

confidence: 99%

Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma

Wang,

Liu,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and accounts for more than 90% of primary liver cancer. The advent of immune checkpoint inhibitor (ICI)-related therapies combined with angiogenesis inhibition has revolutionized the treatment of HCC in late-stage and unresectable HCC, as ICIs alone were disappointing in treating HCC. In addition to the altered immune microenvironment, abnormal lipid metabolism in the liver has been extensively characterized in various types of HCC. Stains are known for their cholesterol-lowering properties and their long history of treating hypercholesterolemia and reducing cardiovascular disease risk. Apart from ICI and other conventional therapies, statins are frequently used by advanced HCC patients with dyslipidemia, which is often marked by the abnormal accumulation of cholesterol and fatty acids in the liver. Supported by a body of preclinical and clinical studies, statins may unexpectedly enhance the efficacy of ICI therapy in HCC patients through the regulation of inflammatory responses and the immune microenvironment. This review discusses the abnormal changes in lipid metabolism in HCC, summarizes the clinical evidence and benefits of stain use in HCC, and prospects the possible mechanistic actions of statins in transforming the immune microenvironment in HCC when combined with immunotherapies. Consequently, the use of statin therapy may emerge as a novel and valuable adjuvant for immunotherapies in HCC.

show abstract

Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions

Cited by 12 publications

References 156 publications

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review

Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma

Contact Info

Product

Resources

About